Roivant Sciences Ltd
ROIV15.040USD
-0.050-0.33%
收盘 09/19, 16:00（美东）报价延迟15分钟
10.26B总市值
亏损市盈率 TTM
关于 Roivant Sciences Ltd 公司
Roivant Sciences Ltd. 是一家生物制药公司，致力于通过加速重要药物的开发和商业化来改善患者的生活。该公司的产品线包括免疫学、肿瘤学、血液学和皮肤病学等各个治疗领域的候选产品。其产品线包括 IMVT-1402 和 batoclimab，它们是针对 FcRn 的完全人源单克隆抗体，正在开发用于多种 IgG 介导的自身免疫适应症；brepocitinib，一种 TYK2 和 JAK1 的小分子抑制剂，正在开发用于治疗皮肌炎和非感染性葡萄膜炎；mosliciguat，一种吸入性可溶性 sGC 激活剂，正在开发用于治疗与间质性肺病相关的肺动脉高压，此外还有其他临床阶段的分子；和 namilumab 是一种完全人源单克隆抗体，针对粒细胞-巨噬细胞集落刺激因子，一种与结节病等炎症性疾病有关的炎症细胞因子。
公司简介
公司代码ROIV
公司名称Roivant Sciences Ltd
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
员工数量750
证券类型Ordinary Share
年结日Dec 03
公司地址7Th Floor, 50 Broadway
城市LONDON
上市交易所NASDAQ Global Select Consolidated
国家United Kingdom
邮编SW1H 0DB
电话4412955950
网址http://roivant.com/
公司代码ROIV
上市日期Dec 03, 2020
CEODr. Eric Venker, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
-0.47%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
192.15K
-1.83%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
98.58K
+14.50%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
91.51K
+14.01%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
+4.20%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
39.44K
+48.40%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.50M
-0.47%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
192.15K
-1.83%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
98.58K
+14.50%
收入明细
FY2025Q1
业务USD
名称
营收
占比
VTAMA
55.13M
0.00%
地区USD
名称
营收
占比
United States
55.13M
0.00%
业务
地区
业务USD
名称
营收
占比
VTAMA
55.13M
0.00%
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
其他
55.12%
持股股东
持股股东
占比
Dexcel Pharma Technologies, Ltd.
15.06%
SB Investment Advisers (UK) Limited
8.78%
Fidelity Management & Research Company LLC
8.13%
Ramaswamy (Vivek)
7.16%
The Vanguard Group, Inc.
5.75%
其他
55.12%
股东类型
持股股东
占比
Investment Advisor
26.26%
Investment Advisor/Hedge Fund
19.67%
Hedge Fund
15.83%
Corporation
15.06%
Private Equity
11.50%
Individual Investor
11.10%
Research Firm
2.05%
Pension Fund
0.51%
Venture Capital
0.45%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
2023Q1
340
722.66M
96.55%
+15.87M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Dexcel Pharma Technologies, Ltd.
102.85M
15.13%
--
--
Jul 01, 2024
SB Investment Advisers (UK) Limited
61.85M
9.1%
-204.82K
-0.33%
Mar 31, 2025
Fidelity Management & Research Company LLC
51.67M
7.6%
+2.36M
+4.80%
Mar 31, 2025
Ramaswamy (Vivek)
50.64M
7.45%
-1.89M
-3.60%
Jun 20, 2025
The Vanguard Group, Inc.
40.68M
5.98%
-3.32M
-7.54%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
37.01M
5.44%
-465.70K
-1.24%
Mar 31, 2025
Viking Global Investors LP
46.01M
6.77%
-1.80M
-3.76%
Mar 31, 2025
Morgan Stanley Investment Management Inc. (US)
31.00M
4.56%
+731.14K
+2.42%
Mar 31, 2025
QVT Financial LP
65.79M
9.68%
--
--
Mar 31, 2025
Rubric Capital Management LP
17.77M
2.61%
-2.23M
-11.16%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
iShares Health Innovation Active ETF
0%
Clough Select Equity ETF
0%
Pacer Lunt MidCap Multi-Factor Alternator ETF
0%
BNY Mellon US Small Cap Core Equity ETF
0%
Vanguard ESG U.S. Stock ETF
0%
iShares Health Innovation Active ETF
占比0%
Clough Select Equity ETF
占比0%
Pacer Lunt MidCap Multi-Factor Alternator ETF
占比0%
BNY Mellon US Small Cap Core Equity ETF
占比0%
Vanguard ESG U.S. Stock ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
